News
LA JOLLA, Calif., May 06, 2025--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe ...
Hosted on MSN4mon
Equillium stock touches 52-week low at $0.52 amid market challengesEquillium Inc . (NASDAQ:EQ) shares have reached a 52-week low, dipping to $0.52, as the biotechnology firm, currently valued at $23 million, faces a challenging market environment. According to ...
Hosted on MSN3mon
Equillium (EQ) Upgraded to Buy: Here's What You Should KnowEquillium, Inc. (EQ) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one ...
Breakthrough Therapy designation and meeting request to discuss potential for Accelerated Approval submitted to FDA, feedback expected during May 2025 Equillium, Inc. (Nasdaq: EQ), a clinical ...
LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory ...
--(BUSINESS WIRE)-- Equillium, Inc. (EQ) (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe ...
LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory ...
LA JOLLA, Calif., November 13, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe ...
Equillium, Inc. is a clinical-stage biotechnology company that engages in the development of novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback